GlassScriptPhysician profile
Teddy Efkarpides
NPI 1356325526
$511.87
in general payments reported to CMS, 2019-2025
11 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $70.10 · 2023: $46.70 · 2024: $135 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $85.86 | 2024-2025 | Gvoke Hypopen |
| Zimmer Biomet Holdings, INC. | $84.49 | 2021-2022 | |
| Mannkind Corporation | $60.98 | 2025 | |
| Treace Medical Concepts, INC. | $54.77 | 2022 | |
| Paratek Pharmaceuticals, INC. | $49.88 | 2021 | |
| Nevro Corp. | $46.70 | 2023 | Senza |
| Abbott Laboratories | $46.58 | 2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $24.04 | 2024 | Ozempic, Rybelsus |
| Medtronic, INC. | $22.37 | 2025 | Inceptiv |
| Neurocrine Biosciences, INC. | $21.38 | 2024 | |
| Ascensia Diabetes Care US INC. | $14.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teddy Efkarpides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.